Endocrine and anti-tumour effects in breast cancer patients treated neo-adjuvantly with the aromatase inhibitor, letrozole

被引：0
|
作者：
Miller, WR [1 ]
Dixon, JM [1 ]
Telford, J [1 ]
Marson, L [1 ]
Bellamy, C [1 ]
Kurian, K [1 ]
MacFarlane, L [1 ]
Anderson, TJ [1 ]
机构：
[1] Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland
来源：
BRITISH JOURNAL OF CANCER | 1999年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P304
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [41] Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry
    Tomáš Pavlík
    Ondřej Májek
    Jan Mužík
    Jana Koptíková
    Lubomír Slavíček
    Jindřich Fínek
    David Feltl
    Rostislav Vyzula
    Ladislav Dušek
    BMC Public Health, 12
  • [42] Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
    Seo, Da Hea
    Cho, Yongin
    Lee, Sujin
    Park, Seho
    Kim, Seung-Il
    Park, Byeong Woo
    Rhee, Yumie
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (03): : 579 - +
  • [43] Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole
    Vani, S. Arul Vijaya
    Ananthanarayanan, P. H.
    Kadambari, D.
    Harichandrakumar, K. T.
    Niranjjan, R.
    Nandeesha, H.
    CLINICA CHIMICA ACTA, 2016, 459 : 53 - 56
  • [44] EFFECTS OF DENOSUMAB ON QUATITATIVE ULTRASOUND AND DXA MEASUREMENTS IN AROMATASE INHIBITOR-TREATED BREAST CANCER WOMEN
    Catalano, A.
    Morabito, N.
    Basile, G.
    Agostino, R. M.
    Gaudio, A.
    Bellone, F.
    Papalia, M.
    Scarcella, C.
    La Fauci, M. M.
    Ferro, C.
    Morini, E.
    Natale, G.
    Lasco, A.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S275 - S276
  • [45] A comparison of survival rates in elderly breast cancer patients treated with surgery or primary endocrine therapy with aromatase inhibitors
    Morrow, E. S.
    Lannigan, A.
    Stallard, S.
    Mallon, E.
    Doughty, J.
    Romics, L.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 44 - 44
  • [46] Erratum to: Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells
    Aleksandra Filipović
    Ylenia Lombardo
    Monica Faronato
    Joel Abrahams
    Eric Aboagye
    Quang-De Nguyen
    Barbara Borda d’Aqua
    Anne Ridley
    Andrew Green
    Emad Rahka
    Ian Ellis
    Chiara Recchi
    Natasa Przulj
    Anida Sarajlić
    Jean-Rene Alattia
    Patrick Fraering
    Mahendra Deonarain
    R. Charles Coombes
    Breast Cancer Research and Treatment, 2014, 148 : 463 - 463
  • [47] A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
    Wang, X.
    Huang, J.
    Wenyan, C.
    Sun, Z.
    Wei, S.
    Wang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S371 - S371
  • [48] Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients
    Kallak, T. Kunovac
    Baumgart, J.
    Evers, A. Stavreus
    Poromaa, I. Sundstrom
    Moby, L.
    Kask, K.
    Norjavaara, E.
    Kushnir, M. M.
    Bergquist, J.
    Nilsson, K.
    CLIMACTERIC, 2012, 15 (05) : 473 - 480
  • [49] Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I
    Shen, Yunfu
    Yang, You
    Wang, Zi
    Lin, Wanjun
    Feng, Na
    Shi, Meina
    Liu, Jiachen
    Ma, Wenzhe
    BRITISH JOURNAL OF PHARMACOLOGY, 2024, 181 (21) : 4262 - 4278
  • [50] Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
    Sun, Shengliang
    Wang, Fuchao
    Dou, Honglei
    Zhang, Longqiang
    Li, Jiwen
    ONCOTARGETS AND THERAPY, 2016, 9 : 6029 - 6036
12345